Second primary malignant neoplasms in patients treated for Hodgkin's disease at St Bartholomew's Hospital

Hematological Oncology
M S DorreenT A Lister

Abstract

The incidence of second malignant neoplasms (SMN's) was investigated in a group of 529 patients with Hodgkin's Disease (HD) treated at St Bartholomew's Hospital (SBH). SMN's were seen in 27 of these patients giving an incidence rate three and a half times that expected in an age and sex matched normal population (p = much less than 0.001). The incidence rate was higher in those receiving multiple chemotherapy and radiotherapy for relapsed HD compared with those receiving primary radiotherapy, chemotherapy or chemotherapy with adjuvant radiotherapy (p = 0.02). However, the increased incidence rate in those patients treated with chemotherapy on relapse, may reflect in part a delayed effect of their primary therapy, since the incidence rate in the primary treatment group only becomes significantly raised after six years. When allowance was made for this delay the difference between the two groups was no longer significant. The incidence rates for Non-Hodgkin's Lymphoma (NHL) and myelogenous leukaemia were 32 and 57 times those expected, compared with only two and a half times the expected rate for non-haematological SMN's (p = much less than 0.001). The four acute myeloid leukaemias (AML) all occurred within five years of treatmen...Continue Reading

References

Apr 26, 1975·Lancet·G P CanellosR E Johnson
Nov 1, 1978·Journal of the National Cancer Institute·R R ReimerR C Young
Sep 1, 1977·Cancer·H KimR F Dorfman
Mar 1, 1979·The New England Journal of Medicine·J G KrikorianH S Kaplan
Jul 28, 1977·The New England Journal of Medicine·R R ReimerR C Young
May 13, 1978·British Medical Journal·A R TimothyA E Jones
Mar 18, 1978·British Medical Journal·S B SutcliffeJ S Malpas
Oct 1, 1977·Cancer·J C ArseneauV T DeVita
Dec 8, 1977·The New England Journal of Medicine·C N ColemanH S Kaplan
Nov 30, 1972·The New England Journal of Medicine·J C ArseneauV T DeVita
Jul 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W J TesterV T DeVita
Dec 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerP F Wrigley
Jan 26, 1980·British Medical Journal·P ValagussaG Bonadonna
Oct 15, 1980·Cancer·M BaccaraniG Papa
Sep 1, 1982·Cancer Treatment Reviews·D SchmählI Wagner

❮ Previous
Next ❯

Citations

Jun 1, 1987·Journal of Clinical Pathology·M A HortonT A Lister
Mar 1, 1987·Baillière's Clinical Haematology·M S Dorreen
Apr 6, 2002·Clinics in Laboratory Medicine·Harold R SchumacherFermina Mazzella

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Australian and New Zealand Journal of Medicine
R RowlandG Ward
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Michael Cohen-WolkowiezMeropenem Study Team
© 2021 Meta ULC. All rights reserved